Ophthalmic Lens Market Size to Grow by USD 11.80 billion | Increasing Prevalence of Refractive Errors to Drive Growth | Technavio
NEW YORK, Dec. 8, 2021 /PRNewswire/ -- Some of the primary growth drivers for the ophthalmic lens market are the increasing prevalence of refractive errors, technological advances in ophthalmic lenses, and initiatives to create awareness about the benefits and advances in ophthalmic lenses.
The ophthalmic lens market size is expected to grow by USD 11.80 bn from 2020 to 2025. The growth momentum of the market will accelerate at a CAGR of 4.38%. The market is expected to post a year-over-year growth rate of 4.03%.
Are you looking for customized information related to the ophthalmic lens market? Speak to Our Analyst Now
Key Vendor Offerings The key vendors of the ophthalmic lens market and their offerings are mentioned below:
Bausch Health Companies Inc. - The company offers ophthalmic lens such as intraocular lenses and others.
Carl Zeiss AG - The company offers ophthalmic lens named Spectacle Lenses.
EssilorLuxottica - The company offers ophthalmic lens under the brand name Stellest lens.
HOYA Corp. - The company offers ophthalmic lens such as Vivinex and more.
Johnson and Johnson Inc. - The company offers ophthalmic lens under the brand name iLASIK.
For additional highlights on the key vendors and their offerings, View Our Free Sample
Regional Analysis
37% of the growth will originate from North America.
The US is a key country for the ophthalmic lens market in North America.
Market growth in this region will be slower than the growth of the market in North America, Europe, Asia, and ROW.
The increasing prevalence of refractive errors, the growing aging population, increasing healthcare expenditure, and the strong market presence of leading vendors will drive the ophthalmic lens market growth in North America over the forecast period.
View Our Free Sample to learn about the contribution of each region of the market
Notes:
The ophthalmic lens market size is expected to accelerate at a CAGR of 4.38% during the forecast period.
The ophthalmic lens market is segmented by product (Spectacle lens, Contact lens, and IOLs) and geography (North America, Europe, Asia, and ROW).
The market is fragmented due to the presence of many vendors holding significant market share.
The research report offers information on several market vendors, including Bausch Health Companies Inc., Carl Zeiss AG, EssilorLuxottica, HOYA Corp., Johnson and Johnson Inc., Nikon Corp., Novartis AG, Rodenstock GmBH, Seiko Holdings Corp., and The Cooper Companies Inc.
Optical Biometry Devices Market: The optical biometry devices market has been segmented by product (SS-OCT-based optical biometers, OLCR-based optical biometers, and PCI-based optical biometers), end-user (hospitals, ASCs, and others), and geography (North America, Europe, Asia, and ROW).Download Free Sample Report
Electroretinograph Market: The electroretinograph market has been segmented by product (fixed ERG and portable ERG), application (clinical and research), and geography (North America, Europe, Asia, and ROW). Download Free Sample Report
Ophthalmic Lens Market Scope
Report Coverage
Details
Page number
120
Base year
2020
Forecast period
2021-2025
Growth momentum & CAGR
Accelerate at a CAGR of 4.38%
Market growth 2021-2025
USD 11.80 billion
Market structure
Fragmented
YoY growth (%)
4.03
Regional analysis
North America, Europe, Asia, and ROW
Performing market contribution
North America at 37%
Key consumer countries
US, China, Germany, India, and France
Competitive landscape
Leading companies, competitive strategies, consumer engagement scope
Companies profiled
Bausch Health Companies Inc., Carl Zeiss AG, EssilorLuxottica, HOYA Corp., Johnson and Johnson Inc., Nikon Corp., Novartis AG, Rodenstock GmBH, Seiko Holdings Corp., and The Cooper Companies Inc.
Market Dynamics
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, market condition analysis for the forecast period
Customization purview
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.
About Us Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Swedish Orphan Biovitrum AB (publ) (Sobi®) has established a medium term note programme with a framework amount of SEK 10 billion or the equivalent thereof in EUR (the "MTN Programme").
For this purpose, Sobi has prepared a base prospectus, which...
OMRON Healthcare Co., Ltd. based in Muko, Kyoto Prefecture, Japan, announces to be the official sponsor of May Measurement Month (MMM,) a global campaign to raise awareness of blood pressure screening and promote hypertension prevention, detection,...
Today, RaySearch Laboratories AB (publ) publishes its Annual Report for the financial year 2023. The report is held available on RaySearch's website, under the section Investors.
This information is information that RaySearch Larboratiories AB...
Shareholders of Zinzino AB (publ) are hereby invited to the annual general meeting on Monday, May 27, 2024, at 1:30 PM at the company's premises at Hulda Mellgrens gata 5 in Gothenburg. Registration begins at 1:15 PM.
The company aims to webcast the...
Implantica AG (publ), a med-tech company at the forefront of bringing advanced technology into the body, is publishing its annual report for the fiscal year 2023. The annual report is now available on the company's website.
"Implantica had a very...
Revenue amounted to ?498.8m (?419.3m), an increase of 18.9% with an organic growth of 14.2%.Operating profit (EBIT) was ?19.0m (?10.7m), an increase of 78.0%, representing an operating margin of 3.8% (2.6%).Net profit amounted to ?6.5m (?2.1m), which...